Saturday 2 November 2024

The Pharma Letter Podcast — Episode 12 — Mastering the microbiome

Biotechnology
Simon Wentworth
9 March 2022
episode12-b

More on this story...

Biotechnology
New show of faith in microbiome with EnteroBiotix financing
7 September 2021
Biotechnology
Takeda leads Big Pharma in microbiome-targeting treatments
17 August 2021
Biotechnology
Third clinical program bought by AI-based microbiome specialist
27 April 2022
Biotechnology
Seres Therapeutics falls despite positive Phase III results with SER-109
24 May 2022


Companies featured in this story

More ones to watch >


Today's issue

ESSA Pharma tank as it drops Phase II masofaniten study
Pharmaceutical
ESSA Pharma tank as it drops Phase II masofaniten study
2 November 2024
Pharmaceutical
Teva presents new data on SC olanzapine
2 November 2024
Pharmaceutical
FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread
1 November 2024
Biotechnology
Ono says no to Equillium’s itolizumab
1 November 2024
Pharmaceutical
Semaglutide shows superior improvement in both liver fibrosis and MASH resolution
1 November 2024
Pharmaceutical
AbbVie and Gedeon Richter partner on neuropsychiatric conditions
1 November 2024
Biosimilars
Celltrion’s SC infliximab making rapid strides in US market
1 November 2024

Company Spotlight

"Revitope Oncology, Inc. is a privately funded cancer therapeutics company with a focus on innovative tumor-specific antibody based biotherapeutics."




More Features in Biotechnology

Ono says no to Equillium’s itolizumab
1 November 2024
Roche will aim to tackle gene therapy challenges through Dyno deal
1 November 2024
Mixed data on bepranemab in early Alzheimer’s
1 November 2024
Lundbeck reports strong trial results for Vyepti in migraine prevention
31 October 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze